Darren Wakefield

Darren Wakefield has more than 16 years of experience in the chemical modification, bioconjugation and delivery of nucleic acids. At MirusBio he development the polymer and formulation techniques which led to development of dynamic polyconjugates (DPCs) used in the targeted delivery of siRNA. These developments led to MirusBio’s acquisition by Roche. At Roche he led a team that developed more bio-compatible delivery vehicles (DPC’s) which increased the threptic window 10-fold over the original DPC. Then at Arrowhead he led the polymer, oligonucleotide synthesis, discovery analytics and DMPK groups, work from these groups helped get multiply modalities into the clinic. Darren is a named inventor on over 80 patents and has 15 publications.